DOCSLIB.ORG

The New Valeant: Delivering on Our Commitments J.P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The New Valeant: Delivering on Our Commitments J.P The New Valeant: Delivering on Our Commitments J.P. Morgan Healthcare Conference January 10, 2017 Forward-Looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding expected future performance of Valeant Pharmaceuticals International, Inc. (“Valeant” or the “Company”), including statements reiterating guidance, the anticipated growth of and plans for the Company’s operating and reportable segments, the anticipated timing of the closing of certain of the Company’s recent divestitures and the anticipated use of proceeds from such divestitures, the anticipated receipt of clinical data for certain of our pipeline products and the expected timing of such data, the anticipated steps and phases for certain of our R&D projects and the expected timing of such steps and phases, the anticipated submission, approval and launch dates for certain of our pipeline products and R&D programs, the expected timing of the loss of exclusivity of certain of our products and the estimated impact of such loss of exclusivity, anticipated debt reduction and repayment (including our ability to pay down debt and the availability of cash flow and asset sales proceeds for such purpose), and the Company’s mission and the plans, goals and strategies related thereto. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in Valeant’s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, except as required by law. 2 Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures including EBITDA. Management uses non-GAAP measures as key metrics in the evaluation of Company performance and the consolidated financial results. The Company believes these non-GAAP measures are useful to investors in their assessment of our operating performance and the valuation of our Company. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors. However, non-GAAP financial measures are not prepared in accordance with GAAP, as they exclude certain items as described herein. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. 3 We Have Stabilized - Reiterating 2016 Guidance OUR MISSION To Improve People’s Lives With Our Healthcare Products STABILIZE TURNAROUND TRANSFORM 2016 2017-2018 2018+ Focus on specialty driven markets w/above average growth rates Paid down debt Lead in our categories Attracted new talent Invest in pipeline/quality/product launches New Product Approvals Launch new products Derm Recovery Strengthen balance sheet Salix Growth Reallocate spending on high ROI Balance organic and inorganic growth Launched new segments programs Improve gross profit 4 Address legacy Issues Significant Progress in 2016 / Delivering on Commitments Streamlined Portfolio – Divested (or agreed to divest) 3 Skincare Brands, Dendreon, Delta (Brazil), Vietnam/Indonesia, Brodalumab EU Rights, Ruconest, OEM Business, Other Built New Leadership Team Launched New Prior Authorization Program for Dermatology/Dermatology Rx Recovery Continued Consistent Growth in Consumer Business Partnered with Wilson’s Disease Association Initiated Xifaxan New Formulation Activities/PCP Strategy Stabilized Salesforce Launched Relistor® Oral Tablets Won 18-0 Vote from Brodalumab FDA Advisory Committee Licensed Novel Bowel Cleansing Product Candidate Introduced PreserVision® AREDS 2 Formula + Multivitamin Launched Bausch + Lomb ULTRA® for Presbyopia contact lenses Reduced Permanent Debt – Paid down ~$1.84B in full year 2016; $294M in Q4 (exceeded $1.7B commitment for 2016) 5 Delivering on Commitments: Divestitures • Upon completion of the transactions announced today, we will have generated asset sale proceeds of ~$2.35B (upfront) and future milestones of ~$0.35B, or total potential proceeds of $2.7B • We have simplified our operating model by divesting or agreeing to divest: CeraVe, AcneFree & AMBI Delta (Brazil) Dendreon Euvipharm (Vietnam) Synergetics OEM Armoxindo (Indonesia) Ruconest Paragon Brodalumab EU Rights Cosmederme (Canada) 6 Delivering on Commitments: Divestitures • Announced sale of CeraVe, AcneFree and DIVESTITURE AMBI skincare brands to L’Oreal for $1.3B in cash • Reshaping consumer product portfolio in STRATEGIC RATIONALE response to compelling in-bound interest from global beauty company • Substantial return on investment PURCHASE PRICE • +20x annualized earnings contribution to VRX TIMING • Expected to close in Q1 2017 USE OF PROCEEDS • Pay down term loan debt 7 Delivering on Commitments: Divestitures • Announced sale of Dendreon to Sanpower DIVESTITURE Group for $819.9M in cash • Exiting non-core oncology business in U.S. STRATEGIC RATIONALE Diversified Products segment • Premium to purchase price in February 2015 PURCHASE PRICE • ~7x multiple of EBITDA TIMING • Expected to close in Q2 2017 USE OF PROCEEDS • Pay down term loan debt 8 Delivering on Commitments: New Leadership Team New Leadership Hires Paul Herendeen Christina Ackermann Bill Humphries Executive Vice President, Finance Executive Vice President Executive Vice President, Chief Financial Officer General Counsel Dermatology Scott Hirsch Louis Yu Sam Eldessouky Senior Vice President, Business Chief Quality Officer Senior Vice President Strategy Corporate Controller Expanded Roles Tom Appio Tracy Valorie Dennis Asharin Mark McKenna Senior Vice President, Executive Vice Senior Vice President Senior Vice President, Manufacturing and Supply President/President, Int’l Bausch + Lomb GI Chain Joe Gordon Barb Purcell Kelly Webber Chuck Hess Senior Vice President/General Senior Vice President Senior Vice President, GM, Surgical Manager, Neurology, Bausch + Lomb Generics and Obagi Human Resources + Primary Care Sales Force Expansion 9 Delivering on Commitments: Stabilized Valeant Sales Force Quarterly Sales Force Retention 94.0% 93.6% 91.1% 89.2% 1Q 2016 2Q 2016 3Q 2016 4Q 2016 Delivering on Commitments: Strengthened Balance Sheet Commitment Result • Repay $1.7B permanent debt in 2016 Achieved $1.84B • Complete all 2017 scheduled amortization Achieved payments by year-end • Evaluate/complete asset sales within 6 months Achieved/Continuing We continue to expect free cash flow and non-core asset sales to reduce debt by more than $5B within 18 months from Aug. 9th 2016 11 Delivering on Commitments: Grew GI/Salix Business • Promoted brands in the portfolio grew +10% YoY with 4% growth from H1 to H2 2016 • Successfully stabilized sales force in H2 compared to H1 with 45% reduction in voluntary turnover • Initiated primary care salesforce expansion in Q4 • Xifaxan continues to drive performance of Salix business with projected +17% Y/Y growth and 4% growth in H2 v. H1 GI Promoted Brands TRx Growth 2014 2015 2016 1,331,032 +10% 1,207,401 +16% 1,041,332 Annual TRx Creating the “New Valeant” OUR MISSION To Improve People’s Lives With Our Healthcare Products STABILIZE TURNAROUND TRANSFORM 2016 2017-2018 2018+ Focus on specialty driven markets Paid down debt w/above average growth rates Lead in our categories Attracted new talent Invest in pipeline/quality/product New Product Approvals launches Launch new products Derm Recovery Strengthen balance sheet Balance organic and Salix Growth Reallocate spending on high ROI inorganic growth Launched new segments programs Improve gross profit 13 Address legacy Issues Invest in R&D/Quality/New Product Launches R&D PROGRAM HIGHLIGHTS % of R&D Launch Timeframe Programs 43 R&D Facilities 2017-2019 ~80% 2020-beyond ~20% # R&D/Quality 1,000+ Employees Derm, Y/Y Increase in Other, 20 38% R&D Spending 23 GI, 16 Total Company active R&D projects ~135 B+L, 76 Expected new product launches 50+ in 2017 14 R&D Catalysts in 2017 • SAN-300 (Rheumatoid Arthritis) Phase II data read out H1 • enVista® Trifocal (Intraocular Lens) Initiate IDE study in H1 • New Material (Ophthalmic Viscosurgical Device); Initiate IDE in H1 • Loteprednol Gel 0.38% (Ocular Inflammation) Complete Phase III enrollment • IDP-120 (Acne) Initiate Phase III
Load more

Recommended publications
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • COVID-19 Treatment and Vaccine Tracker This Document Contains an Aggregation of Publicly Available Information from Validated Sources
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES PhRMA Begin Phase 1 trials in late Polyclonal hyperimmune Alliance among Takeda, CSL Behring, Wall Street Journal spring. To patients between 1 globulin (H-IG), formerly N/A Biotest AG, Bio Products Laboratory, Pre-clinical Pink Sheet December 2020 and December known at TAK-888 LFB, and Octapharma Press release from the 2021 alliance Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Korea Herald Antibodies from recovered 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 UPI COVID-19 patients Celltrion press release Super-antibody or antibody 4 cocktail to target potential N/A Celltrion Pre-clinical Celltrion press release mutations of SARS-CoV-2 Antibodies from recovered BioSpace 5 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 6 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • Fidelity® Select Portfolio® Pharmaceuticals Portfolio
    Quarterly Holdings Report for Fidelity® Select Portfolio® Pharmaceuticals Portfolio November 30, 2020 PHR-QTLY-0121 1.810707.116 Schedule of Investments November 30, 2020 (Unaudited) Showing Percentage of Net Assets Common Stocks – 98.3% Shares Value Shares Value Biotechnology – 17.6% Bausch Health Cos., Inc. (Canada) (a) 535,300 $ 9,937,694 Biotechnology – 17.6% Bristol‑Myers Squibb Co. 1,295,680 80,850,432 Acceleron Pharma, Inc. (a) 128,800 $ 15,207,416 Catalent, Inc. (a) 75,400 7,248,956 Amgen, Inc. 137,400 30,508,296 Elanco Animal Health, Inc. (a) 172,400 5,273,716 Argenx SE (a) 17,400 4,983,924 Eli Lilly & Co. 416,961 60,730,370 Ascendis Pharma A/S sponsored ADR (a) 51,300 8,655,849 GlaxoSmithKline PLC sponsored ADR 348,300 12,813,957 Atea Pharmaceuticals, Inc. 39,800 1,326,136 Harmony Biosciences Holdings, Inc. 133,077 5,467,801 Athenex, Inc. (a) (b) 166,800 2,273,484 Horizon Therapeutics PLC (a) 316,100 22,262,923 BioNTech SE ADR (a) (b) 50,148 6,230,388 Intra‑Cellular Therapies, Inc. (a) 107,000 2,529,480 Blueprint Medicines Corp. (a) 80,300 8,678,824 Johnson & Johnson 337,850 48,880,138 ChemoCentryx, Inc. (a) 6,400 352,960 Merck & Co., Inc. 515,936 41,476,095 Galapagos Genomics NV sponsored ADR (a) 36,900 4,524,309 Nektar Therapeutics (a) (b) 368,233 6,035,339 Generation Bio Co. (b) 16,738 807,106 Novartis AG sponsored ADR 441,496 40,101,082 Generation Bio Co.
    [Show full text]
  • Case 5:19-Cv-01087-OLG Document 55 Filed 05/07/20 Page 1 of 11
    Case 5:19-cv-01087-OLG Document 55 Filed 05/07/20 Page 1 of 11 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS SAN ANTONIO DIVISION RAMON D. JOHNSON, II, § Plaintiffs, § § v. § § Civil Action No. 5:19-cv-01087-OLG NOVARTIS PHARMACEUTICALS § CORPORATION; TARO § PHARMACEUTICALS USA, INC.; § BAUSCH HEALTH US, LLC; SUN § PHARMACEUTICAL INDUSTRIES § LTD.; and TORRENT PHARMA, INC., § Defendants. § ORDER On this day, the Court considered the status of the above-captioned case. Currently pending before the Court are Defendants Sun Pharmaceutical Industries and Tara Pharmaceuticals USA’s Motion to Dismiss (docket no. 8); Defendant Novartis Pharmaceuticals Corporation’s Motion to Dismiss (docket no. 9); Defendant Torrent Pharma, Inc.’s Motion to Dismiss (docket no. 12); and Defendant Bausch Health US, LLC’s Motion to Dismiss (docket no. 23). Also pending are Plaintiff’s Motion for Leave to File a Combined Rebuttal to Defendants’ Replies in Support of their Motions to Dismiss (docket no. 44) and Plaintiff’s Motion for Leave to File a First Amended Complaint for a Civil Case and To Edit the Style of the Case (docket no. 47). Having considered each of these Motions and the record, the Court finds that Defendants’ Motions to Dismiss should be GRANTED. BACKGROUND On September 10, 2019, Plaintiff Ramon D. Johnson II (“Plaintiff”) initiated this lawsuit alleging that he suffered personal injuries resulting from his use of two drugs: Minocycline and Carbamazepine. See docket no. 1. Specifically, Plaintiff alleges that he was prescribed 1 Case 5:19-cv-01087-OLG Document 55 Filed 05/07/20 Page 2 of 11 Minocycline in April 2013 for an unrelated condition.
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Bausch Health Update – 3Q19 Seventh Consecutive Quarter of Total Company Organic Revenue Growth1,2
    3Q 19 Financial Results Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of Commission and the Canadian Securities Administrators, which risks and uncertainties are applicable securities laws (collectively, “forward-looking statements”), including, but not limited incorporated herein by reference. In addition, certain material factors and assumptions have to, statements regarding Bausch Health's future prospects and performance (including the been applied in making these forward-looking statements, including, without limitation, Company’s 2019 full-year guidance and targeted three-year CAGR1 of revenue growth and assumptions regarding our 2019 full-year guidance with respect to currency impact, adjusted Adjusted EBITDA (non-GAAP) growth), planned dermatology growth, anticipated growth of SG&A expense (non-GAAP) and the Company’s ability to continue to manage such expense revenues in Salix business unit, anticipated revenue from TRULANCE®, the expected impact in the manner anticipated, the anticipated timing and extent of the Company’s R&D expense, on long-term growth of new product approvals, the anticipated submission, approval and the expected timing and impact of loss of exclusivity for certain of our products, expected base launch dates for certain of our pipeline products and R&D programs, the anticipated timing of performance, expectations regarding our newly acquired TRULANCE® product and commencement of studies or other development work of our pipeline products and R&D expectations regarding gross margin, assumptions respecting our targeted three-year CAGR programs, the anticipated timing of the loss of exclusivity of certain of our products and the of revenue growth and Adjusted EBITDA (non-GAAP) growth including, without limitation, expected impact of such loss of exclusivity on our financial condition, expected reported expectations on constant currency and mid-point of Feb.
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]
  • SCHEDULE of INVESTMENTS (Unaudited) HEALTH CARE FUND
    SCHEDULE OF INVESTMENTS (Unaudited) June 30, 2021 HEALTH CARE FUND SHARES VALUE SHARES VALUE COMMON STOCKS† - 99.7% Jazz Pharmaceuticals plc* 701 $ 124,526 GlaxoSmithKline plc ADR 2,917 116,155 HEALTHCARE-PRODUCTS - 30.2% Novartis AG ADR 1,250 114,050 Abbott Laboratories 3,480 $ 403,436 Viatris, Inc. 7,920 113,177 Thermo Fisher Scientific, Inc. 784 395,504 Cardinal Health, Inc. 1,962 112,011 Danaher Corp. 1,454 390,195 Elanco Animal Health, Inc.* 3,174 110,106 Medtronic plc 2,655 329,565 Perrigo Company plc 2,294 105,180 Intuitive Surgical, Inc.* 319 293,365 Teva Pharmaceutical Industries Ltd. ADR* 10,447 103,425 Stryker Corp. 1,051 272,976 PRA Health Sciences, Inc.* 540 89,213 Edwards Lifesciences Corp.* 2,164 224,125 Bausch Health Companies, Inc.* 3,026 88,722 Boston Scientific Corp.* 4,995 213,586 Neurocrine Biosciences, Inc.* 855 83,209 IDEXX Laboratories, Inc.* 328 207,148 Organon & Co.* 2,475 74,893 Align Technology, Inc.* 313 191,243 Sarepta Therapeutics, Inc.* 871 67,712 Baxter International, Inc. 2,171 174,766 ResMed, Inc. 679 167,387 Total Pharmaceuticals 5,624,909 Zimmer Biomet Holdings, Inc. 994 159,855 BIOTECHNOLOGY - 20.5% West Pharmaceutical Services, Inc. 399 143,281 Amgen, Inc. 1,348 328,575 10X Genomics, Inc. — Class A* 649 127,087 Moderna, Inc.* 1,229 288,790 STERIS plc 616 127,081 Gilead Sciences, Inc. 3,768 259,464 Avantor, Inc.* 3,564 126,558 Illumina, Inc.* 493 233,293 Novocure Ltd.* 549 121,779 Regeneron Pharmaceuticals, Inc.* 389 217,272 Hologic, Inc.* 1,761 117,494 Vertex Pharmaceuticals, Inc.* 1,023 206,268 PerkinElmer, Inc.
    [Show full text]
  • Current Sustaining Member Companies
    CURRENT SUSTAINING MEMBER COMPANIES Member Since (alpabetical order) 1976 3M Medical Markets Center 2019 EMD Serono, Inc. 2018 Neurocrine Biosciences 2019 10-Square Solutions 2017 Exelixis 1998 Northrop Grumman Technology Services 1954 Abbott Laboratories, Inc. 2016 Express Scripts Federal Pharmacy 1963 NOVARTIS PHARMACEUTICALS 2013 AbbVie Inc. 2010 Federal Practitioner 2016 NOVO NORDISK, Inc. 2017 ACADIA Pharmaceuticals, Inc. 2018 Foundation Medicine, Inc. 2018 Organogenesis 2003 Alcon Laboratories, Inc. 2018 Fujifilm Medical Systems USA 2004 OTSUKA AMERICA PHARMACEUTICAL, Inc. 2017 Alkermes, Inc. 1989 Genentech Inc. 2018 Pacira Pharmaceuticals Inc. 2002 Allergan, Inc. 2006 Gilead Sciences 2018 Paratek Pharmaceuticals 2013 Arbor Pharmaceuticals, Inc. 2013 Golden State Medical Supply, Inc. 1990 PFIZER PHARMACEUTICALS 2014 Argentum Medical, LLC 2019 Greenwich Biosciences 2017 Pharmacyclics, LLC 2019 ASM Research, LLC 2013 Gulf Coast Pharmaceuticals Plus, LLC 2009 REGENESIS BIOMEDICAL, INC. 1986 Astellas Pharma US, Inc. 2008 Heritage Health Solutions, Inc. 2011 REMUND GROUP, LLC 1995 AstraZeneca 2017 Hill-Rom Company 2018 Rigel Pharmaceuticals 2018 Avanir Pharmaceuticals 2018 Hu-Friedy Manufacturing Co 2016 Sage Products, LLC 2017 Bausch Health Companies, Inc. 2019 Incyte Corporation 2018 Sage Therapeutics 1985 Baxter Healthcare Corporation 2015 Intercept Pharmaceuticals 2000 SANOFI-AVENTIS 1996 Bayer Corporation 2018 IT Cadre 2004 Siemens Medical Solutions 1954 BD 1989 J & J Health Care Systems, Inc. 2002 SMITH & NEPHEW, INC. 2018 Beacon Health Options, Inc. 2014 Jazz Pharmaceuticals Inc. 2013 STRYKER ORTHOPAEDICS 2002 Biogen 2007 Karl Storz Endoscopy America 2018 Sun Pharmaceutical 1995 Boehringer Ingelheim Pharm Inc. 2010 LLC Federal Solutions 1999 SUNOVION PHARMACEUTICALS INC 1954 Bristol-Meyers Squibb 2014 Lovell Government Services LLC 2016 TAIHO ONCOLOGY, INC.
    [Show full text]
  • Schedule of Investments Health Care Fund
    SCHEDULE OF INVESTMENTS December 31, 2019 HEALTH CARE FUND SHARES VALUE SHARES VALUE COMMON STOCKS† - 99.6% Insulet Corp.* 657 $ 112,478 Henry Schein, Inc.* 1,575 105,084 PHARMACEUTICALS - 34.7% Masimo Corp.* 636 100,526 Johnson & Johnson 4,586 $ 668,960 Abiomed, Inc.* 572 97,577 Merck & Company, Inc. 5,761 523,963 Repligen Corp.* 819 75,758 Pfizer, Inc. 12,923 506,323 NuVasive, Inc.* 897 69,374 Bristol-Myers Squibb Co. 6,640 426,222 Tandem Diabetes Care, Inc.* 1,101 65,631 AbbVie, Inc. 4,443 393,383 Eli Lilly & Co. 2,925 384,433 Total Healthcare-Products 5,147,377 CVS Health Corp. 4,523 336,014 BIOTECHNOLOGY - 19.5% Cigna Corp. 1,486 303,872 Amgen, Inc. 1,701 410,060 Becton Dickinson and Co. 1,090 296,447 Gilead Sciences, Inc. 4,793 311,449 Zoetis, Inc. 2,074 274,494 Vertex Pharmaceuticals, Inc.* 1,184 259,237 Allergan plc 1,431 273,564 Biogen, Inc.* 844 250,440 McKesson Corp. 1,258 174,007 Illumina, Inc.* 729 241,838 DexCom, Inc.* 710 155,305 Regeneron Pharmaceuticals, Inc.* 589 221,158 AmerisourceBergen Corp. — Class A 1,699 144,449 Alexion Pharmaceuticals, Inc.* 1,516 163,955 Cardinal Health, Inc. 2,621 132,570 Seattle Genetics, Inc.* 1,314 150,138 AstraZeneca plc ADR 2,516 125,448 Incyte Corp.* 1,669 145,737 Jazz Pharmaceuticals plc* 818 122,111 BioMarin Pharmaceutical, Inc.* 1,575 133,166 Novartis AG ADR 1,243 117,700 Amarin Corporation plc ADR*,1 5,809 124,545 ,1 Canopy Growth Corp.* 5,456 115,067 Exact Sciences Corp.* 1,307 120,871 Elanco Animal Health, Inc.* 3,845 113,235 Alnylam Pharmaceuticals, Inc.* 1,044 120,238 GlaxoSmithKline
    [Show full text]